Retina

Additionally, the FDA approved a monthly dosing option for some patients who may benefit from resuming this dosing schedule across approved indications.

CoTx-101 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).

Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and potentially blindness.

Anat Loewenstein, MD, discusses the transformative impact of home OCT and AI on monitoring retinal diseases at AAO 2025.

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

OPGx-LCA5 is designed to address a form of Leber congenital amaurosis that results from biallelic mutations in the LCA5 gene, which encodes the lebercilin protein, the investigators explained.

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform treatment and improve children's vision.

Tsu Shan Chambers shares how the film "My Eyes" uses authentic storytelling to raise awareness of inherited eye disease and the importance of preventive vision care.

The addition comes as the company accelerates development of its long-acting anti-VEGF program and advances its HA-binding platform.

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

The funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study and the completion of the STELLA natural history study

Tsu Shan Chambers, optometrist and filmmaker, blends clinical insight and storytelling to highlight preventable vision loss, retinitis pigmentosa, and the power of ability over disability in her socially conscious film.

Deborah A. Ferrington, PhD, highlights how breakthroughs in imaging, AI, and stem cell research are reshaping ophthalmology.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

Catch up on news you may have missed at the meeting in Orlando, like the effects of GLP-1 drugs on eye health and a potential sign of cardiovascular disease.

REMAIN is the long-term extension of the phase 2b/3 RESTORE trial evaluating MCO-010 in retinitis pigmentosa (RP).

A study reveals that systemic chemotherapy significantly reduces mortality in retinoblastoma, while targeted treatments lower enucleation rates.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk

The CNPV program was announced by the FDA in June 2025 and offers companies the opportunity to reduce standard application review times from 10–12 months to just 1–2 months.

According to the company, FALCON aimed to provide “a better understanding of how autosomal dominant optic atrophy (ADOA) disease parameters change over time to inform potential future interventional clinical trials.”